D
Danielle Horyniak
Researcher at Monash University
Publications - 49
Citations - 2178
Danielle Horyniak is an academic researcher from Monash University. The author has contributed to research in topics: Population & Poison control. The author has an hindex of 16, co-authored 42 publications receiving 1925 citations. Previous affiliations of Danielle Horyniak include University of California, San Diego & Alfred Hospital.
Papers
More filters
Journal ArticleDOI
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
Paul K. Nelson,Bradley Mathers,Benjamin C Cowie,Holly Hagan,Don C. Des Jarlais,Danielle Horyniak,Louisa Degenhardt,Louisa Degenhardt +7 more
TL;DR: More IDUs have anti-HCV than HIV infection, and viral hepatitis poses a key challenge to public health, which will inform efforts to prevent and treat HCV and HBV in IDUs.
Journal ArticleDOI
Epidemiology of Substance Use among Forced Migrants: A Global Systematic Review.
TL;DR: A need to integrate substance use prevention and treatment into services offered to forced migrants, particularly in camp settings is suggested, and efforts to develop and evaluate interventions to reduce substance use and related harms are needed.
Journal ArticleDOI
“Let’s get Wasted!” and Other Apps: Characteristics, Acceptability, and Use of Alcohol-Related Smartphone Applications
TL;DR: The majority of popular alcohol-related apps encouraged alcohol consumption and apps estimating blood alcohol concentration were widely available but were highly unreliable.
Journal ArticleDOI
Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results
Danielle Horyniak,Danielle Horyniak,Peter Higgs,Peter Higgs,Peter Higgs,Rebecca Jenkinson,Rebecca Jenkinson,Louise Degenhardt,Louise Degenhardt,Mark Stoove,Mark Stoove,Thomas Kerr,Matthew Hickman,Campbell Aitken,Paul Dietze,Paul Dietze +15 more
TL;DR: The authors' efforts to recruit a sample of largely out-of-treatment PWID were limited by drug market characteristics at the time, where fluctuating heroin availability has led to large numbers of PWID accessing low-threshold OST.
Journal ArticleDOI
Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
Briony Larance,Louisa Degenhardt,Nicholas Lintzeris,Jimmy D. Bell,Adam R. Winstock,Paul Dietze,Richard P. Mattick,Robert Ali,Danielle Horyniak +8 more
TL;DR: BNX was less commonly and less frequently injected than BPN, but both sublingual medications were diverted more than liquid MET and the median street price of BnX was equivalent to that for BPN.